Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | MTOR | P42345 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ATR | Q13535 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272785 | 0.86 | KMT2A (0.75) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL18003190 | 0.85 | HTT (0.65) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL18003396 | 0.83 | HTT (0.74) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL10224015 | 0.82 | KMT2A (0.70) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL1271201 | 0.82 | KMT2A (1.00) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL1271558 | 0.81 | KMT2A (0.67) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL1271420 | 0.81 | MTOR (1.00) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL1271826 | 0.81 | MAPT (0.67) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL1270760 | 0.80 | MTOR (0.72) | MAPTKMT2ALMNAHTTALDH1A1 | |
| SCHEMBL1272267 | 0.79 | KMT2A (0.76) | MAPTKMT2ALMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | claimed |
| EP-1979325-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | claimed |
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| EP-1979325-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | TYMP, TYMS, PIK3CA | MAPT 2984/4885KMT2A 2550/4885LMNA 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.